type in your search and press enter
Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors
You May Also Like
miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
New MRG-106 Phase 1 cutaneous T-cell lymphoma clinical trial data releasedExpansion of the MRG-106 ...
Heat Biologics Announces Agreement to Acquire Pelican Therapeutics
Acquisition brings $15.2 million CPRIT grant to fund 70-patient Phase I trial DURHAM, N.C., ...
